SCHEMBL14749776

SCHEMBL14749776

CCOC(=O)C1(COc2c(C)ccc(OC)c2OC)CCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ GAA P10253 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ POLB P06746 3/20 0.38
▸ HSD11B1 P28845 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TUBB4A P04350 1/20 0.36
▸ TUBB P07437 1/20 0.36
▸ TUBA3C P0DPH7 1/20 0.36
▸ TUBA1B P68363 1/20 0.36
▸ TUBA4A P68366 1/20 0.36
▸ TUBB4B P68371 1/20 0.36
▸ TUBB3 Q13509 1/20 0.36
▸ TUBB2A Q13885 1/20 0.36
▸ TUBB8 Q3ZCM7 1/20 0.36
▸ TUBA3E Q6PEY2 1/20 0.36
▸ TUBA1A Q71U36 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14749775 0.86 DGAT1 (0.40) L3MBTL1MEN1KMT2AGAAALDH1A1
SCHEMBL2591854 0.80 PDE4D (0.40) L3MBTL1MEN1KMT2AGAAPOLB
SCHEMBL14737665 0.79 ALDH1A1 (0.45) L3MBTL1MEN1KMT2AGAAALDH1A1
SCHEMBL2593060 0.78 HSD17B1 (0.44) L3MBTL1MEN1KMT2AALDH1A1POLB
SCHEMBL2592146 0.77 L3MBTL1 (0.38) L3MBTL1MEN1KMT2AGAAPOLB
SCHEMBL14737149 0.77 PDE4D (0.52) —
SCHEMBL2591396 0.77 POLQ (0.37) L3MBTL1MEN1KMT2A
SCHEMBL2591497 0.75 PDE4D (0.41) L3MBTL1MEN1KMT2APOLB
SCHEMBL14750017 0.75 DGAT1 (0.39) MEN1KMT2AMAPT
SCHEMBL2588055 0.74 ALDH1A1 (0.39) L3MBTL1MEN1KMT2AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 — — US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A L3MBTL1 1456/4885MEN1 3420/4885KMT2A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback